Clinical Trial Update: Myfortic - Treatment for Extensive cGvHD [Phase 3]

View source ↗

Summary

Phase 3 trial of Myfortic for extensive chronic graft-versus-host disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• MYFORTIC (MYCOPHENOLIC ACID)

Snippet

Sponsor: European Society for Blood and Marrow Transplantation | Conditions: Graft vs Host Disease | Phase 3 | Status: TERMINATED